button bars forest bayes pooled summary circles
 
deaths (OS)

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
camrelizumab based treatment vs. sorafenib 1 0.62 [0.49; 0.79], 1 RCT, I2=0% conclusive
unassessable degree of certainty

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons